Chronic Kidney Disease Drug Pipeline Analysis Report 2025

Chronic kidney disease (CKD) is a progressive condition characterized by a gradual loss of kidney function, affecting over 850 million people globally. It is projected to be the fifth leading cause of years of life lost by 2040. There is a high unmet clinical need for better chronic kidney disease therapeutics, as current treatment options, such as renin-angiotensin system inhibitors, only slow disease progression. The growing focus on novel therapies, including SGLT2 inhibitors, endothelin receptor antagonists, and regenerative medicine, is driving drug pipeline advancements. Emerging chronic kidney disease drug candidates aim to improve outcomes and address complications, supporting significant market growth in the coming years.

Report Coverage

The Chronic Kidney Disease Drug Pipeline Insight Report by the publisher gives comprehensive insights into chronic kidney disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic kidney disease. The chronic kidney disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic kidney disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic kidney disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic kidney disease.

Chronic Kidney Disease Drug Pipeline Outlook

Chronic kidney disease is a long-term condition where the kidneys gradually lose their function, often due to diabetes, hypertension, or genetic factors. This disease affects more than millions of people and leads to end-stage renal failure if left untreated. Current pipeline drug candidates aim to address the progressive nature of chronic kidney disease, focusing on slowing its progression and improving kidney function.

Chronic kidney disease treatments aim to control underlying causes, such as hypertension and diabetes, with medications like ACE inhibitors and SGLT2 inhibitors. Dialysis or kidney transplants may be necessary for advanced stages. Research is focused on developing novel therapeutics that target fibrosis, inflammation, and renal repair to slow disease progression and enhance patient outcomes.

Chronic Kidney Disease Epidemiology

Chronic kidney disease affects over 850 million people worldwide and is projected to become the fifth leading cause of years of life lost by 2040. In the United States, 14% of adults are impacted, while 13% of Japan's adult population suffers from chronic kidney disease. The prevalence in India has reached epidemic levels, with 4%-20% affected. Approximately 7.2 million people are diagnosed with chronic kidney disease stages 1-5 in the United Kingdom, with 3.25 million in later stages.

Chronic Kidney Disease Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of chronic kidney disease drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• RNA-based Therapies
• Cell-based Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Chronic Kidney Disease - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total chronic kidney disease clinical trials.

Chronic Kidney Disease - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the chronic kidney disease pipeline analysis include small molecules, monoclonal antibodies, gene therapies, RNA-based therapies, and cell-based therapies. The chronic kidney disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic kidney disease.

Chronic Kidney Disease Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the chronic kidney disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic kidney disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic kidney disease clinical trials:

• AstraZeneca
• Novo Nordisk A/S
• Zydus Lifesciences Limited
• EHL Bio Co., Ltd.
• Chinook Therapeutics, Inc.
• Disc Medicine, Inc.
• Bayer
• Shandong Suncadia Medicine Co., Ltd.
• Regeneron Pharmaceuticals
• Astellas Pharma, Inc.
• Genexine, Inc.
• Amgen
• Sanofi
• Keryx Biopharmaceuticals
• Alexion Pharmaceuticals, Inc.
• Eli Lilly and Company

Chronic Kidney Disease Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic kidney disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic kidney disease drug candidates.

Drug: Dapagliflozin

AstraZeneca is sponsoring a Phase IV study to evaluate the efficacy and safety of dapagliflozin in Chinese adults with chronic kidney disease. This single-arm, open-label trial aims to assess its role in preventing chronic kidney disease progression. The study, which began on September 10, 2024, is expected to be completed by June 21, 2027, with approximately 700 participants.

Drug: NNC0519-0130

A Phase 2 study, sponsored by Novo Nordisk A/S, is investigating the efficacy, safety, and pharmacokinetics of NNC0519-0130 in reducing kidney damage in individuals with chronic kidney disease (CKD), with or without type 2 diabetes. With an estimated enrollment of 465 participants, the study is expected to be completed by July 30, 2026.

Drug: AZD4144

AstraZeneca is sponsoring a Phase 1b study to assess the safety, tolerability, and pharmacodynamics of AZD4144 in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). The randomized, placebo-controlled trial will enroll around 28 participants. The study is expected to conclude by August 21, 2025, and includes a 28-day treatment period along with follow-up assessments.

Reasons To Buy This Report

The Chronic Kidney Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for chronic kidney disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic kidney disease collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Chronic Kidney Disease - Pipeline Insight Report

• Which companies/institutions are leading the chronic kidney disease drug development?
• What is the efficacy and safety profile of chronic kidney disease pipeline drugs?
• Which company is leading the chronic kidney disease pipeline development activities?
• What is the current chronic kidney disease commercial assessment?
• What are the opportunities and challenges present in the chronic kidney disease drug pipeline landscape?
• What is the efficacy and safety profile of chronic kidney disease pipeline drugs?
• Which company is conducting major trials for chronic kidney disease drugs?
• Which companies/institutions are involved in chronic kidney disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in chronic kidney disease?

This product will be delivered within 3-5 business days.